2011•国际外科学杂志Requires access

Development of sunitinib in the treatment of imatinib-resistant gastrointestinal stromal tumors

Ke Wang, Kefeng Ding

Abstract

Sunitinib malate (SU11248 ,Sutent) is an orally available small-molecule multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities.In 2006 sunitinib was approved by FDA for imatinib intolerant gastrointestinal stromal tumors (GIST) patients or imatinib resistant GIST patients.This article review the molecular-based mechanism,the mechanism of resistance,the biomarker,the clinical trials and the adverse effects of sunitinib in the treatment of imatinib-resistant GIST. Key words: Sunitinib; Gastrointestinal stromal tumors; Resistance

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Sunitinib, GiST, Sunitinib malate, Imatinib, Tyrosine-kinase inhibitor, Medicine, Stromal tumor, Stromal cell